Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer

BACKGROUND: In many clinical trials designed to assess the efficacy of anticancer treatments, overall survival (OS) is often used as a primary endpoint despite its several points of weakness. METHODS: This study evaluated the role of progression-free survival (PFS) in the first three lines of treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicero, Giuseppe, De Luca, Rossella, Dieli, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975605/
https://www.ncbi.nlm.nih.gov/pubmed/29872317
http://dx.doi.org/10.2147/OTT.S151276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975605/
https://www.ncbi.nlm.nih.gov/pubmed/29872317
http://dx.doi.org/10.2147/OTT.S151276

Ejemplares similares